Oleg Borisenko co-authored health economic analysis of Barostim for heart failure

10

Aug 2018

An article “An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany” was published in the BMC Cardiovascular Disorders.

The study concluded that Baroreflex activation therapy (BAT) using the Barostim neo™ device (CVRx Inc., Minneapolis, MN, USA) compared with optimized medical management in patients with advanced chronic heart failure (NYHA class III) who were not eligible for treatment with cardiac resynchronization therapy, can be cost-effective from a statutory health insurance perspective in Germany over a lifetime horizon.

BAT led to an incremental cost of €33,185 (95% credible interval [CI] €24,561–38,637) and incremental benefits of 1.78 [95% CI 0.45–2.71] life-years and 1.19 [95% CI 0.30–1.81] quality-adjusted life-years (QALYs). This resulted in an incremental cost-effectiveness ratio of €27,951/QALY (95% CI €21,357–82,970). BAT had a 59% probability of being cost-effective at a willingness-to-pay threshold of €35,000/QALY (but 84% at a threshold of €52,000/QALY).

Read the full article here.

The latest related news

29

Nov 2022

On November 18, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) announced that sixteen applications for Innovation Funding of the new forms of care were accepted. These applications relate to the funding announcement of March 17, 2021. Most projects relate to interdisciplinary or cross-sectoral care and pathways.

Read more

23

Nov 2022

MedTech Europe and MTRC completed a mapping of reimbursement and funding of medical procedures and technologies. MTRC analysed all these pathways by screening the situation in 32 European countries between July and October 2022. The result is an overview of all the current payment schemes for innovative medical technologies and procedures. The mapping also presents the current concrete initiatives aimed at transforming healthcare systems and/or reimbursement and funding systems already implemented by some European countries.

Read more

22

Nov 2022

On October 27, 2022, the BfArM (Federal Institute for Drugs and Medical Devices) published the final version of the 2023 OPS procedure coding classification. The OPS, together with the ICD-10-GM (International Statistical Classification of Diseases and Related Health Problems, 10th revision, German Modification), forms the basis for the reimbursement systems in outpatient and inpatient care in Germany.

Read more

18

Nov 2022

On October 28, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) reported that 231 applications were received for innovation funding of healthcare research projects.

Read more

03

Nov 2022

On October 17, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) published the decision, recommending the transfer to standard care for another completed project. The project relates to the improvement of the management of cancer patients.

Read more